ArticleFrontiers in cellular and infection microbiology2024
Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan.
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Secretion of Extracellular Microvesicles Induced by a Fraction ofInternational journal of molecular sciences · 2025Article
- Infections withJournal of clinical medicine · 2025Article
- Treatment response evaluation in anFrontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections (BSIs) are a critical concern in pediatric onco-hematological patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT), leading to a major impact on morbidity, long-term hospitalization, and mortality. We retrospectively analyzed 202 BSIs in 145 patients, consisting of 128 with hematological malignancies, one with a solid tumor, and 16 with non-malignant hematological diseases. We collected data on patient demographics, clinical characteristics, pathogen distribution, and antimicrobial pathogen susceptibility. Gram-positive infections were the most frequent at (58.4%), followed by gram-negative (41%), and fungal infections (0.5%). Particularly, the majority of these infections occurred during the induction phase of chemotherapy, where 94 (46.5%) BSI episodes were recorded, predominantly in neutropenic patients (88.3%). The consolidation phase experienced lower BSIs (11.8%); among these patients (54.1%) were non-neutropenic. BSIs observed in (23.7%) of patients in the maintenance phase, with a higher proportion (66.6%) being neutropenic. Among the 7 patients who underwent HSCT, BSIs occurred in (4.9%) cases, mainly (70%) due to neutropenia. The most prevalent pathogens were Staphylococcus epidermidis (19.8%), Staphylococcus hominis (16.3%), and Escherichia coli (8.4%). The study highlights the critical need for vigilant monitoring and customized infection management strategies to enhance patient outcomes across chemotherapy phases and HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.